secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cue Biopharma, Inc. (CUE)
CIK:        0001645460
Form:       8-K
Filed at:   2024-06-07T23:59:59+00:00
Accession:  0000950170-24-070566
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Cue Biopharma appoints Michael J. Fox to board; grants 48,800-share option
--------------------------------------------------------------------------

- Michael J. Fox appointed to Board and Compensation Committee effective June 5, 2024.
- Received option to purchase 48,800 shares vesting over three years (1/3 at one year, then quarterly).
- Stockholders elected all 7 director nominees; Passeri received 13,099,740 for, 765,119 withheld.
- Ratified RSM US LLP as auditor for FY2024 with 32,418,349 for, 1,635,231 against.
- Non-binding say-on-pay passed with 11,745,009 for, 1,924,707 against, 20,311,373 broker non-votes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645460/000095017024070566/0000950170-24-070566-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645460/000095017024070566/cue-20240605.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-070566

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer